研究者詳細 - 中鉢　正太郎

論文 - 中鉢　正太郎

分割表示 82 件中 61 - 80 件目／全件表示 >>

Plasma sE-cadherin and the plasma sE-cadherin/sVE-cadherin ratio are potential biomarkers for chronic obstructive pulmonary disease

Shirahata, T., Nakamura, H., Nakajima, T., Nakamura, M., Chubachi, S., Yoshida, S., Tsuduki, K., Mashimo, S., Takahashi, S., Minematsu, N., Tateno, H., Asano, K., Fujishima, S. and Betsuyaku, T.

Biomarkers 23 （ 5 ） 414 - 421 2018年07月

研究論文（学術雑誌）, 共著, ISSN 1366-5804

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by airway inflammation with endothelial dysfunction. Cadherins are adhesion molecules on epithelial (E-) and vascular endothelial (VE-) cells. Soluble (s) cadherin is released from the cell surface by the effects of proteases including matrix metalloproteinases (MMPs). OBJECTIVE: The aim of this study was to examine the associations of sE-/sVE-cadherin levels in plasma with the development of COPD. METHODS: Plasma sE-/VE-cadherin levels were measured by an enzyme-linked immunosorbent assay in 115 patients with COPD, 36 symptomatic smokers (SS), 63 healthy smokers (HS) and 78 healthy non-smokers (HN). sE-cadherin and MMP-7 levels in epithelial lining fluid (ELF) were measured in 24 patients (12 COPD and 12 control). RESULTS: Plasma sE-cadherin levels and sE-cadherin/sVE-cadherin ratios were significantly higher in COPD and SS than in HS and HN groups, while plasma sVE-cadherin levels were lower in COPD than in HS and HN groups (p < 0.0001). sE-cadherin levels paralleled the severity of airflow limitation in both plasma (p < 0.01) and ELF (p < 0.05), while plasma sVE-cadherin levels were inversely correlated with the extent of emphysema (p < 0.05). MMP-7 levels were correlated with sE-cadherin levels in ELF. CONCLUSIONS: Plasma sE-cadherin levels and sE-cadherin/sVE-cadherin ratios are potential biomarkers for COPD.

Access to Document (DOI)

Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

Sakurai, K., Chubachi, S., Irie, H., Tsutsumi, A., Kameyama, N., Kamatani, T., Koh, H., Terashima, T., Nakamura, H., Asano, K. and Betsuyaku, T.

BMC Pulm Med 18 （ 1 ） 65 2018年05月

研究論文（学術雑誌）, 共著, ISSN 1471-2466

BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of inflammation in chronic obstructive pulmonary disease (COPD) patients. But, a meaningful threshold and the longitudinal changes are unknown. We aimed to investigate the association between NLR and the clinical characteristics of COPD patients and to determine a meaningful threshold and the longitudinal changes for NLR. METHODS: Keio University and its affiliate hospitals conducted an observational COPD cohort study over 3 years. We performed a blood examination and a pulmonary function test. Blood examination was completed at baseline and annually thereafter, at a time when the disease was stable. Two hundred seventy-four patients who had at least 3 blood examinations over 3 years were included. RESULTS: Baseline NLR was correlated with baseline C-reactive protein (CRP) (r = 0.18, p = 0.003) and SAA (r = 0.34, p < 0.001). We defined an NLR score of 2.7 as the arbitrary cut-off value based on upper quartile points. COPD patients with NLR >/= 2.7 were older (p = 0.037), had a lower BMI (p = 0.005) and a lower %FEV1 (p = 0.0003) compared to patients with NLR < 2.7. Receiver-operating-characteristic (ROC) curves showed the optimal cutoff for the baseline NLR in the predicting moderate/severe exacerbation to be 2.7, which was same as the upper quartile points. Follow-up analysis over 3 years revealed that the differences in the trends of NLR among the three groups based on the categories of exacerbations (moderate or severe, mild, no exacerbation) were significant (p = 0.006). CONCLUSIONS: NLR is associated with COPD severity and exacerbations. For predicting exacerbations, we estimated the threshold of NLR to be 2.7 at baseline. TRIAL REGISTRATION: Clinical trial registered with the University Hospital Medication Information Network ( UMIN000003470 , April 10, 2010).

Access to Document (DOI)

Effects of long-term cigarette smoke exposure on bone metabolism, structure, and quality in a mouse model of emphysema

Sasaki, M., Chubachi, S., Kameyama, N., Sato, M., Haraguchi, M., Miyazaki, M., Takahashi, S., Nakano, T., Kuroda, Y., Betsuyaku, T. and Matsuo, K.

PLoS One 13 （ 1 ） e0191611 2018年

研究論文（学術雑誌）, 共著, ISSN 1932-6203

Smoking is a common risk factor for both chronic obstructive pulmonary disease (COPD) and osteoporosis. In patients with COPD, severe emphysema is a risk factor for vertebral fracture; however, the effects of smoking or emphysema on bone health remain largely unknown. We report bone deterioration in a mouse model of emphysema induced by nose-only cigarette smoke (CS) exposure. Unexpectedly, short-term exposure for 4-weeks decreased bone turnover and increased bone volume in mice. However, prolonged exposure for 20- and 40-weeks reversed the effects from suppression to promotion of bone resorption. This long-term CS exposure increased osteoclast number and impaired bone growth, while it increased bone volume. Strikingly, long-term CS exposure deteriorated bone quality of the lumbar vertebrae as illustrated by disorientation of collagen fibers and the biological apatite c-axis. This animal model may provide a better understanding of the mechanisms underlying the deterioration of bone quality in pulmonary emphysema caused by smoking.

Access to Document (DOI)

Relationship between diminution of small pulmonary vessels and emphysema in chronic obstructive pulmonary disease

Mashimo, S., Chubachi, S., Tsutsumi, A., Kameyama, N., Sasaki, M., Jinzaki, M., Nakamura, H., Asano, K., Reilly, J. J., Jr. and Betsuyaku, T.

Clin Imaging 46 85 - 90 2017年11月

研究論文（学術雑誌）, 共著, ISSN 1873-4499

OBJECTIVES: To investigate the relationship between small pulmonary vessels and extent of emphysema on CT in individual lungs with chronic obstructive pulmonary disease (COPD). METHODS: Forty-nine patients were included. The percentage of cross-sectional area of vessels <5mm(2) (%CSA <5) and extent of emphysema were assessed. RESULTS: Less than half of the COPD patients demonstrated an inverse correlation between %CSA <5 and percentage of low attenuation area (LAA%). In the remaining patients, %CSA <5 was homogeneously distributed. CONCLUSION: Not all patients with COPD demonstrated an inverse correlation of the distributions between %CSA <5 and LAA% in individual lungs.

Access to Document (DOI)

The association between dental health and nutritional status in chronic obstructive pulmonary disease

Terashima, T., Chubachi, S., Matsuzaki, T., Nakajima, T., Satoh, M., Iwami, E., Yoshida, K., Katakura, A. and Betsuyaku, T.

Chron Respir Dis 14 （ 4 ） 334 - 341 2017年11月

研究論文（学術雑誌）, 共著, ISSN 1479-9731

Chronic obstructive pulmonary disease (COPD) and periodontitis are chronic inflammatory systemic diseases with common risk factors (smoking and aging). In COPD, poor periodontal health could result in inadequate nutrition, potentially causing loss of muscle volume. The purpose of this case-control study was to examine our hypothesis that COPD patients have poorer periodontal health and poorer nutritional status than non-COPD patients. Periodontal status was assessed using bleeding on probing (BOP), pocket depth (PD), and plaque-control ratio (PCR). Nutritional status was assessed using body mass index, lean body mass, and serum albumin levels. The COPD group ( n = 60) had fewer remaining teeth, greater BOP, greater PD, and lower serum albumin levels compared with smokers without COPD ( n = 41) and nonsmokers ( n = 35; p < 0.001). COPD was an independent risk factor for poor periodontal health, demonstrated by fewer remaining teeth (relative risk (RR), 5.48; p = 0.0024), BOP (RR, 12.8; p = 0.0009), and having >30% of remaining teeth with a PD >/= 4 mm (RR, 4.82; p = 0.011). A significant negative correlation existed between the number of teeth with a PD >/= 4 mm and serum albumin level ( r(2) = 0.127; p = 0.013). We demonstrated that poor periodontal health was associated with hypoalbuminemia, suggesting poor nutritional status and inflammation in COPD.

Access to Document (DOI)

Characteristics of patients with increasing COPD assessment test scores within 3 years

Irie, H., Chubachi, S., Sato, M., Tsutsumi, A., Nakachi, I., Miyao, N., Nishio, K., Nakamura, H., Asano, K. and Betsuyaku, T.

Respir Med 131 101 - 108 2017年10月

研究論文（学術雑誌）, 共著, ISSN 1532-3064

BACKGROUND: The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) is a subjective measure of quality of life. The aim of this study was to examine the characteristics of COPD patients with increasing CAT scores within 3 years. METHODS: Keio University and its affiliate hospitals conducted an observational COPD cohort study over 3 years. St. George's Respiratory Questionnaire (SGRQ) and CAT were completed at baseline and annually thereafter. Patients who had at least 3 CAT scores were included (n = 315). The DeltaCAT score/year and DeltaSGRQ score/year were calculated by the slope between each of the measures and the date of measurement. RESULTS: The median DeltaCAT score/year was 0.4, and DeltaCAT score/year was significantly correlated with DeltaSGRQ total score/year. Using an annual cut-off CAT score of +2 points, patients who deteriorated (n = 79) were older, had lower %FEV1, and more severe emphysema on computed tomography scan at baseline than patients who did not deteriorate. The baseline value was not a determinant of subsequent changes in the CAT score. Longitudinal changes in the CAT score were positively correlated with those in the SGRQ score. CONCLUSIONS: Old age and severe COPD, not the CAT score at one time point, predicted worsening quality of life.

Access to Document (DOI)

Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy

Nomura, H., Takahashi, H., Suzuki, S., Kurihara, Y., Chubachi, S., Kawada, I., Yasuda, H., Betsuyaku, T., Amagai, M. and Funakoshi, T.

J Dermatol 44 （ 7 ） 818 - 821 2017年07月

研究論文（学術雑誌）, 共著, ISSN 1346-8138

Vemurafenib improves survival of melanoma patients. However, cutaneous side-effects commonly occur in them. Nivolumab and ipilimumab are monoclonal antibodies against programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4, both of which regulate excessive T-cell activation. Although these agents induce antitumor immunity against melanoma, the modified immune condition may result in an unexpected adverse reaction which has not been observed previously. Herein, we report a case who manifested severe erythema multiforme-like eruption with mucosal involvement associated with vemurafenib following nivolumab. The patient also subsequently suffered from ipilimumab-induced interstitial pneumonia with refractory course. Such a case has never been reported. This case suggested that dermatologists should pay special attention to unexpected adverse events of these drugs, and carefully observe cutaneous and respiratory status of patients during the treatment of melanoma.

Access to Document (DOI)

Edoxaban treatment for pulmonary arterial thromboembolism associated with azygous vein aneurysm

Mochimaru, T., Kawada, I., Chubachi, S., Tsutsumi, A., Hasegawa, H. and Betsuyaku, T.

Respirol Case Rep 5 （ 3 ） e00223 2017年05月

研究論文（学術雑誌）, 共著, ISSN 2051-3380

A 76-year-old woman, diagnosed 5 years previously with an asymptomatic mediastinal bronchogenic cyst, was referred to our department as the mass had grown slightly larger. Contrast-enhanced computed tomography and magnetic resonance imaging scans revealed an azygous vein aneurysm with a pulmonary arterial thromboembolism. The patient was treated with heparin for 5 days, and anticoagulation therapy with edoxaban was continued for 12 months. The thrombus resolved, and the aneurysm remained unchanged. An azygous vein aneurysm is a very rare condition that causes pulmonary arterial thromboembolism. Although surgical resection is indicated for patients with azygous vein aneurysms with a risk of rupture and pulmonary embolism, we chose anticoagulation therapy because of the patient's advanced age. This case suggests that the azygous vein aneurysm is one of the differential diagnoses for a mediastinal mass and that anticoagulation therapy can be the treatment of choice for pulmonary arterial thromboembolism with an azygous vein aneurysm.

Access to Document (DOI)

Impact of cataract on health-related quality of life in a longitudinal Japanese chronic obstructive pulmonary cohort

Irie, H., Chubachi, S., Sato, M., Sasaki, M., Kameyama, N., Inoue, T., Oyamada, Y., Nakamura, H., Asano, K., Betsuyaku, T. and Keio, Copd Comorbidity Research Group

Chron Respir Dis 1479972317745735 2017年01月

研究論文（学術雑誌）, 共著, ISSN 1479-9731

Cigarette smoking increases the risk of developing both cataract and chronic obstructive pulmonary disease (COPD). The prevalence of cataract and the clinical characteristics of COPD patients with cataract were retrospectively investigated in a 2-year observational COPD cohort. We analyzed 395 patients with complete data on ophthalmologic evaluation (319 subjects with COPD and 76 subjects at risk of COPD). There was no difference in the prevalence of cataract between COPD patients and those at risk (47.0% vs. 42.1%, p = 0.44). Age >/= 75 years, low body mass index, and hypertension were independently associated with cataract as a comorbidity in COPD. The incidence of exacerbation within 2 years was significantly higher in COPD patients with cataract than those without cataract (36.6% vs. 18.3%, p = 0.0019). COPD patients with cataract exhibited significantly higher COPD assessment test score compared to those without cataract (13.7 +/- 8.9 vs. 11.5 +/- 7.2, p = 0.0240). Overall St George's Respiratory Questionnaire score and each component were significantly worse in COPD patients with cataract compared to those without cataract. COPD patients with cataract exhibited poor health-related quality of life and frequent exacerbations. The association between cataract and exacerbations of COPD deserves further attention.

Access to Document (DOI)

Radiologic features of precancerous areas of the lungs in chronic obstructive pulmonary disease

Chubachi, S., Takahashi, S., Tsutsumi, A., Kameyama, N., Sasaki, M., Naoki, K., Soejima, K., Nakamura, H., Asano, K. and Betsuyaku, T.

Int J Chron Obstruct Pulmon Dis 12 1613 - 1624 2017年

研究論文（学術雑誌）, 共著, ISSN 1178-2005

BACKGROUND: Only a few studies have evaluated the radiologic features of pre-existing structural abnormalities where lung cancer may develop. This study aimed to analyze the computed tomography (CT) images of lung areas where new cancer developed in chronic obstructive pulmonary disease (COPD) patients. PATIENTS AND METHODS: We conducted a multicenter, longitudinal cohort study, called the Keio COPD Comorbidity Research, to assess the incidence of lung cancer. Emphysema and interstitial abnormalities were evaluated in 240 COPD patients who had baseline CT scans applicable for further digital analyses. For patients who developed lung cancer during the 3-year follow-up period, the local spherical lung density of the precancerous area was individually quantified. RESULTS: Lung cancer was newly diagnosed in 21 participants (2.3% per year). The percent-age of low attenuation area in patients who developed lung cancer was higher than that of the other patients (20.0% vs 10.4%, P=0.014). The presence of emphysema (odds ratio [OR] 4.2, 95% confidence interval [CI] 1.0-29.0, P=0.049) or interstitial lung abnormalities (OR 15.6, 95% CI 4.4-65.4, P<0.0001) independently increased the risk for lung cancer. Compared with the density of the entire lung, the local density of the precancerous area was almost the same in patients with heterogeneous emphysema, but it was higher in most patients with interstitial abnormalities. CONCLUSION: The presence of emphysema or interstitial abnormalities or a combination of both were independent predictors of lung cancer development in COPD patients. Furthermore, lung cancer most often developed in non-emphysematous areas or in interstitial abnormalities.

Access to Document (DOI)

Identification of five clusters of comorbidities in a longitudinal Japanese chronic obstructive pulmonary disease cohort

Chubachi, S., Sato, M., Kameyama, N., Tsutsumi, A., Sasaki, M., Tateno, H., Nakamura, H., Asano, K., Betsuyaku, T. and Keio, Copd Comorbidity Research Group

Respir Med 117 272 - 9 2016年08月

研究論文（学術雑誌）, 共著, ISSN 1532-3064

BACKGROUND AND OBJECTIVES: Patients with chronic obstructive pulmonary disease (COPD) frequently suffer from various comorbidities. Recently, cluster analysis has been proposed to examine the phenotypic heterogeneity in COPD. In order to comprehensively understand the comorbidities of COPD in Japan, we conducted multicenter, longitudinal cohort study, called the Keio COPD Comorbidity Research (K-CCR). In this cohort, comorbid diagnoses were established by both objective examination and review of clinical records, in addition to self-report. We aimed to investigate the clustering of nineteen clinically relevant comorbidities and the meaningful outcomes of the clusters over a two-year follow-up period. MATERIAL AND METHODS: The present study analyzed data from COPD patients whose data of comorbidities were completed (n = 311). Cluster analysis was performed using Ward's minimum-variance method. RESULTS: Five comorbidity clusters were identified: less comorbidity; malignancy; metabolic and cardiovascular; gastroesophageal reflux disease (GERD) and psychological; and underweight and anemic. FEV1 did not differ among the clusters. GERD and psychological cluster had worse COPD assessment test (CAT) and Saint George's respiratory questionnaire (SGRQ) at baseline compared to the other clusters (CAT: p = 0.0003 and SGRQ: p = 0.00046). The rate of change in these scores did not differ within 2 years. The underweight and anemic cluster included subjects with lower baseline ratio of predicted diffusing capacity (DLco/VA) compared to the malignancy cluster (p = 0.036). CONCLUSIONS: Five clusters of comorbidities were identified in Japanese COPD patients. The clinical characteristics and health-related quality of life were different among these clusters during a follow-up of two years.

Access to Document (DOI)

Determinants of chronic obstructive pulmonary disease severity in the late-elderly differ from those in younger patients

Haraguchi, M., Nakamura, H., Sasaki, M., Miyazaki, M., Chubachi, S., Takahashi, S., Asano, K., Jones, P. W., Betsuyaku, T. and Keio, Copd Comorbidity Research Group

BMC Res Notes 9 7 2016年01月

研究論文（学術雑誌）, 共著, ISSN 1756-0500

BACKGROUND: Although the age range of chronic obstructive pulmonary disease (COPD) patients is broad, few studies have focused on the effects of age on disease characteristics. METHODS: Keio University and affiliated hospitals established an observational COPD cohort. Patients were assessed using high resolution computed tomography (CT) to quantify emphysema, health status using the COPD assessment test (CAT) and the St. George's Respiratory Questionnaire (SGRQ), spirometry, echocardiogram, dual X-ray absorption of bone, biomarkers and comorbid diagnoses. We examined the characteristics of COPD patients aged 75 and over compared with patients below 75. RESULTS: A total of 443 patients comprising 252 patients aged <75 years and 191 patients aged >/=75 years, were enrolled. Emphysematous changes on CT and prevalence of possible pulmonary hypertension were greater in late-elderly patients. The slope of the relationship between CT emphysema densitometry score and forced expiratory volume in 1 s was significantly less steep in the late-elderly than the younger patients (p = 0.002). CAT and total SGRQ scores and the frequency of long-term oxygen therapy were significantly higher in the late-elderly with moderate airflow obstruction compared to those of the younger in the same grade, although the opposite was seen in late-elderly patients with very severe airflow obstruction. Hypertension, aortic aneurysm, prostatic hypertrophy, anemia, and cataract are more prevalent in late-elderly patients. CONCLUSIONS: Elderly COPD patients show a varied age-related pattern of disease that warrants specific attention in clinical practice above and beyond assessment of airflow limitation. Trial registration Clinical trial registered with the University Hospital Medical Information Network (UMIN000003470, April 10, 2010).

Access to Document (DOI)

Impact of mild exacerbation on COPD symptoms in a Japanese cohort

Sato, M., Chubachi, S., Sasaki, M., Haraguchi, M., Kameyama, N., Tsutsumi, A., Takahashi, S., Nakamura, H., Asano, K. and Betsuyaku, T.

Int J Chron Obstruct Pulmon Dis 11 1269 - 78 2016年

研究論文（学術雑誌）, 共著, ISSN 1178-2005

BACKGROUND: Patients with COPD might not report mild exacerbation. The frequency, risk factors, and impact of mild exacerbation on COPD status are unknown. OBJECTIVES: The present study was performed to compare features between mild exacerbation and moderate or severe exacerbation in Japanese patients with COPD. PATIENTS AND METHODS: An observational COPD cohort was designed at Keio University and affiliated hospitals to prospectively investigate the management of COPD comorbidities. This study analyzes data only from patients with COPD who had completed annual examinations and questionnaires over a period of 2 years (n=311). RESULTS: Among 59 patients with mild exacerbations during the first year, 32.2% also experienced only mild exacerbations in the second year. Among 60 patients with moderate or severe exacerbations during the first year, 40% also had the same severity of exacerbation during the second year. Findings of the COPD assessment test and the symptom component of the St George's Respiratory Questionnaire at steady state were worse in patients with mild exacerbations than in those who were exacerbation free during the 2-year study period, although the severity of the ratio of predicted forced expiratory volume in 1 second did not differ between them. Severe airflow limitation (the ratio of predicted forced expiratory volume in 1 second <50%) and experience of mild exacerbations independently advanced the likelihood of an elevated COPD assessment test score to >/=2 per year. CONCLUSION: The severity of COPD exacerbation seemed to be temporally stable over 2 years, and even mild exacerbations adversely impacted the health-related quality of life of patients with COPD.

Access to Document (DOI)

Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD

Nakajima, T., Nakamura, H., Owen, C. A., Yoshida, S., Tsuduki, K., Chubachi, S., Shirahata, T., Mashimo, S., Nakamura, M., Takahashi, S., Minematsu, N., Tateno, H., Fujishima, S., Asano, K., Celli, B. R. and Betsuyaku, T.

Dis Markers 2016 4093870 2016年

研究論文（学術雑誌）, 共著, ISSN 1875-8630

Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94 patients with COPD and 31 subjects with productive cough but no airflow obstruction ("at risk"; AR). In these subjects and in 52 healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (p < 0.01). Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels, were negatively related to severe airflow limitation (% FEV1 predicted < 50%; p = 0.005) and severe emphysema as assessed by low attenuation area (LAA) score on chest CT scans (LAA >/= 8.0; p = 0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin C ratios may serve as potential biomarkers for COPD.

Access to Document (DOI)

A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment

Chubachi, S., Yasuda, H., Irie, H., Fukunaga, K., Naoki, K., Soejima, K. and Betsuyaku, T.

Case Rep Oncol Med 2016 1075641 2016年

研究論文（学術雑誌）, 共著, ISSN 2090-6706

Background. Recent clinical trials proven the clinically significant efficacy and tolerability of nivolumab, a programmed death 1 (PD-1) inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC). Case Presentation. Here, we describe the case of a patient who experienced possible "disease flare" immediately after initiation of nivolumab treatment. A 54-year-old man was diagnosed with Stage IIB (T2N1M0) lung adenocarcinoma. After 7 years from recurrence, 10th line chemotherapy, nivolumab, was initiated. Six weeks later, after 3 cycles of nivolumab treatment, rapid lung cancer progression was observed with an increase in the size of the primary lesion, multiple novel nodules on both lungs, and multiple novel brain metastases. Conclusion. We believe that physicians should be made aware that, in a subset of NSCLC patients, disease flare might occur on nivolumab treatment.

Access to Document (DOI)

Evaluation of cigarette smoke-induced emphysema in mice using quantitative micro-computed tomography

Sasaki, M., Chubachi, S., Kameyama, N., Sato, M., Haraguchi, M., Miyazaki, M., Takahashi, S. and Betsuyaku, T.

Am J Physiol Lung Cell Mol Physiol 308 （ 10 ） L1039 - 45 2015年05月

研究論文（学術雑誌）, 共著, ISSN 1522-1504

Chronic cigarette smoke (CS) exposure provokes variable changes in the lungs, and emphysema is an important feature of chronic obstructive pulmonary disease. The usefulness of micro-computed tomography (CT) to assess emphysema in different mouse models has been investigated, but few studies evaluated the dynamic structural changes in a CS-induced emphysema mouse model. A novel micro-CT technique with respiratory and cardiac gating has resulted in high-quality images that enable processing for further quantitative and qualitative analyses. Adult female C57BL/6J mice were repeatedly exposed to mainstream CS, and micro-CT scans were performed at 0, 4, 12, and 20 wk. Emphysema was also histologically quantified at each time point. Air-exposed mice and mice treated with intratracheal elastase served as controls and comparisons, respectively. End-expiratory lung volume, corresponding to functional residual volume, was defined as the calculated volume at the phase of end-expiration, and it evaluated air trapping. The end-expiratory lung volumes of CS-exposed mice were significantly larger than those of air controls at 12 and 20 wk, which was in line with alveolar enlargement and destruction by histological quantification. However, CS exposure neither increased low attenuation volume nor decreased the average lung CT value at any time point, unlike the elastase-instilled emphysema model. CS-exposed mice had rather higher average lung CT values at 4 and 12 wk. This is the first study characterizing a CS-induced emphysema model on micro-CT over time in mice. Moreover, these findings extend our understanding of the distinct pathophysiology of CS-induced emphysema in mice.

Access to Document (DOI)

Polymorphism of LRP5 gene and emphysema severity are associated with osteoporosis in Japanese patients with or at risk for COPD

Chubachi, S., Nakamura, H., Sasaki, M., Haraguchi, M., Miyazaki, M., Takahashi, S., Tanaka, K., Funatsu, Y., Asano, K., Betsuyaku, T. and Keio, Copd Comorbidity Research Group

Respirology 20 （ 2 ） 286 - 95 2015年02月

研究論文（学術雑誌）, 共著, ISSN 1440-1843

BACKGROUND AND OBJECTIVE: Osteoporosis is an important systemic comorbidity of chronic obstructive pulmonary disease (COPD). However, neither its mechanisms nor its risk factors have been fully elucidated. With regard to genetic factors, low-density lipoprotein receptor-related protein 5 (LRP5) A1330V is known to be associated with osteoporosis in the general population, but the influence of this polymorphism in COPD is unknown. The aim of this study was to investigate the potential risk factors of COPD-related bone loss and fracture. METHODS: Keio University and affiliated hospitals have enrolled an observational cohort to investigate the management of COPD comorbidities. To assess risk factors for osteopenia and osteoporosis, bone mineral density (BMD) of the hip and lumbar spine, presence of vertebral fracture, quantitative data on emphysema and airway wall on computed tomography, as well as LRP5 genotype were analysed in patients with or at risk for COPD (n = 270). RESULTS: The percentage of subjects with osteoporosis (T-score </= -2.5), osteopenia (T-score between -1 and -2.5) and a normal BMD (T-score >/= -1) was 15.2%, 35.9% and 48.9%, respectively. T-score was significantly decreased in subjects with LRP5 TT genotype (n = 15) compared with that in those with CC/CT genotype (n = 255) (-1.83 vs. -0.98, P = 0.0167). On multivariate logistic regression analysis, female gender (odds ratio (OR) 10.4; P < 0.0001), severe emphysema (OR 2.3; P = 0.013) and LRP5 TT genotype (OR 3.7; P = 0.031) independently increased the risk of osteopenia/osteoporosis. CONCLUSIONS: This study confirmed the complex pathophysiology of COPD-related osteoporosis, including the influence of gender, clinical phenotype and genetic factors.

Access to Document (DOI)

The reasons for triple therapy in stable COPD patients in Japanese clinical practice

Miyazaki, M., Nakamura, H., Takahashi, S., Chubachi, S., Sasaki, M., Haraguchi, M., Terai, H., Ishii, M., Fukunaga, K., Tasaka, S., Soejima, K., Asano, K., Betsuyaku, T. and Keio, Copd Comorbidity Research group

Int J Chron Obstruct Pulmon Dis 10 1053 - 9 2015年

研究論文（学術雑誌）, 共著, ISSN 1178-2005

BACKGROUND: Triple combination therapy involving long-acting muscarinic antagonists long-acting beta2 agonists, and inhaled corticosteroids has recently become an option for maintenance treatment of COPD. Some add-on clinical trials have reported the benefits of these combinations. However, the process to step up to triple therapy varies for individual cases. METHODS: Keio University and affiliated hospitals conducted an observational COPD cohort study, recruiting patients diagnosed as having COPD by pulmonary physicians and those referred for investigation of possible COPD. Their prescription history and clinical course were retrospectively analyzed based on the physicians' medical records and patient questionnaires. This study was registered with UMIN (UMIN000003470, April 10, 2010). RESULTS: A total of 95 of the 445 COPD patients (21%) were treated with inhaled corticosteroids/long-acting beta2 agonists/long-acting muscarinic antagonists as maintenance therapy, including 12 in COPD Grade I, 31 in Grade II, 38 in Grade III, and 14 in Grade IV, based on the Global Initiative for Chronic Obstructive Lung Disease spirometric grading. For more than half of the patients on triple therapy, the treatment had been intensified due to unsatisfactory improvement of symptoms, and 32% were treated with triple therapy due to comorbid asthma. In contrast, there were COPD patients whose therapy was maintained after starting with triple therapy because of their serious conditions or concurrent exacerbation at diagnosis (8%). CONCLUSION: Triple therapy was often prescribed in the real-life management of COPD, even in patients whose airflow limitation was not severe. To better control symptoms was the major reason for choosing triple therapy, regardless of the severity of COPD, in Japan.

Access to Document (DOI)

Plasma cytokine profiles related to smoking-sensitivity and phenotypes of chronic obstructive pulmonary disease

Nakamura, M., Nakamura, H., Minematsu, N., Chubachi, S., Miyazaki, M., Yoshida, S., Tsuduki, K., Shirahata, T., Mashimo, S., Takahashi, S., Nakajima, T., Tateno, H., Fujishima, S. and Betsuyaku, T.

Biomarkers 19 （ 5 ） 368 - 77 2014年08月

研究論文（学術雑誌）, 共著, ISSN 1366-5804

Chronic obstructive pulmonary disease (COPD) develops only in smoking-sensitive smokers and manifests heterogeneous phenotypes, including emphysema and non-emphysema types. We aimed to identify biomarkers related to the smoking-sensitivity and phenotypes of COPD. Among 240 smokers suggestive of COPD, we studied on four groups defined by % forced expiratory volume in one second (FEV1) and computed tomography-based pulmonary emphysema. Plasma concentrations of 33 inflammatory markers were measured in four groups as well as Non-smokers using multiplex protein arrays. IL-5, IL-7 and IL-13 were identified to be associated with smoking sensitivity and IL-6 and IL-10 were candidate biomarkers for airway-lesion dominant COPD.

Access to Document (DOI)

Analysis of comorbid factors that increase the COPD assessment test scores

Miyazaki, M., Nakamura, H., Chubachi, S., Sasaki, M., Haraguchi, M., Yoshida, S., Tsuduki, K., Shirahata, T., Takahashi, S., Minematsu, N., Koh, H., Nakamura, M., Sakamaki, F., Terashima, T., Sayama, K., Jones, P. W., Asano, K., Betsuyaku, T. and Keio, Copd Comorbidity Research Group

Respir Res 15 13 2014年02月

研究論文（学術雑誌）, 共著, ISSN 1465-993X

BACKGROUND: The chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) is a concise health status measure for COPD. COPD patients have a variety of comorbidities, but little is known about their impact on quality of life. This study was designed to investigate comorbid factors that may contribute to high CAT scores. METHODS: An observational study at Keio University and affiliated hospitals enrolled 336 COPD patients and 67 non-COPD subjects. Health status was assessed by the CAT, the St. Georges Respiratory Questionnaire (SGRQ), and all components of the Medical Outcomes Study Short-Form 36-Item (SF-36) version 2, which is a generic measure of health. Comorbidities were identified based on patients' reports, physicians' records, and questionnaires, including the Frequency Scale for the Symptoms of Gastro-esophageal reflux disease (GERD) and the Hospital Anxiety and Depression Scale. Dual X-ray absorptiometry measurements of bone mineral density were performed. RESULTS: The CAT showed moderate-good correlations with the SGRQ and all components of the SF-36. The presence of GERD, depression, arrhythmia, and anxiety was significantly associated with a high CAT score in the COPD patients. CONCLUSIONS: Symptomatic COPD patients have a high prevalence of comorbidities. A high CAT score should alert the clinician to a higher likelihood of certain comorbidities such as GERD and depression, because these diseases may co-exist unrecognized. TRIAL REGISTRATION: Clinical trial registered with UMIN (UMIN000003470).

Access to Document (DOI)

　前のページ - 次のページ　

中鉢 正太郎

論文 - 中鉢 正太郎

中鉢　正太郎

論文 - 中鉢　正太郎